Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (ChiCTR2600129064) titled 'A Prospective, National, Multicenter, Observational Real-World Study of Acalabrutinib in Chinese Patients with MCL/CLL/SLL (RESA)' on July 30.
Study Type: Observational study
Study Design:
Cohort study
Primary Sponsor: Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Condition:
Mantle cell lymphoma (MCL)
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-07-31
Target Sample Size: 1L CLL/SLL R/RCLL/SLL R/RMCL:160;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=335482
Published by HT Digital Content Services ...